Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only commonly available curative treatment for people with thalassemia major (TM).This work aimed to study the impact of using low dose versus high dose anti thymocyte globulin (ATG (based conditioning regimen on the results of peripheral blood stem cell transplantation in children with βeta- TM.
Methods: This comparative study was established on 40 patients with βeta-thalassemia major (Pesaro class II and/or III) who subjected to (HSCT) from donor who is related. Our patients received the same myeloablative regimen. They were then categorized according to dose of ATG into two groups: group I (Busulfan/Cyclophosphamide/Low dose ATG-30 mg) and group II (Busulfan/Cyclophosphamide/High dose ATG-110 mg).
Results: There was no association between both groups according to the clinical features, transplant related complications in both groups. There was a higher risk of mucositis and infections in high dose group. (P = 0.024 & P = 0.046; respectively). Patients in low dose group achieved faster neutrophil engraftment with median value of (14 days). No difference was found in the incidence of post-transplant viral reactivation, graft versus host disease in both groups.
Conclusions: Pesaro II, III thalassemia patients can safely receive hematopoietic stem cell transplantation (HSCT) with low dose ATG-30 mg regimen and attain the same result.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.